RT Journal Article
SR Electronic
T1 Membranous Nephropathy in the UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.02.23285369
DO 10.1101/2023.02.02.23285369
A1 Hamilton, Patrick
A1 Blaikie, Kieran
A1 Roberts, Stephen A.
A1 Gittins, Matthew
A1 Downie, Mallory L.
A1 Gupta, Sanjana
A1 Voinescu, Catalin
A1 Kanigicherla, Durga
A1 Stanescu, Horia
A1 Kleta, Robert
A1 Brenchley, Paul
YR 2023
UL http://medrxiv.org/content/early/2023/02/04/2023.02.02.23285369.abstract
AB Background Despite MN being one of the most common causes of nephrotic syndrome worldwide, its biological and environmental determinants are poorly understood in large-part due to it being a rare disease. Making use of the UK Biobank, a unique resource holding a clinical dataset and stored DNA, serum and urine for ∼500,000 participants, this study aims to address this gap in understanding.Methods The primary outcome was putative MN as defined by ICD-10 codes occurring in the UK Biobank. Univariate relative risk regression modelling was used to assess the associations between the incidence of MN and related phenotypes with sociodemographic, environmental exposures, and previously described increased-risk SNPs.Results 502,507 patients were included in the study of whom 100 were found to have a putative diagnosis of MN; 36 at baseline and 64 during the follow-up. Prevalence at baseline and last follow-up were 72 and 199 cases/million respectively. At baseline, as expected, the majority of those previously diagnosed with MN had proteinuria, and there was already evidence of proteinuria in patients diagnosed within the first 5 years of follow-up. The highest incidence rate for MN in patients was seen in those homozygous for the high-risk alleles (9.9/100,000 person-years).Conclusion It is feasible to putatively identify patients with MN in the UK Biobank and cases are still accumulating. This study shows the chronicity of disease with proteinuria present years before diagnosis. Genetics plays an important role in disease pathogenesis, with the at-risk group providing a potential population for recall.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding from Kidney Research UK (KRUK) for the Stoneygate Foundation Grant JFS_IN_003_20160914 MLD was supported by the KRESCENT post-doctoral fellowship from the Kidney Foundation of Canada The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was an approved study (I.D. 1618) by UK BioBank (http:/ukbiobank.org).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData held by UK Biobank (http://ukbiobank.org) - access to data is dependent on application directly to UK biobank http://ukbiobank.org